keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/29220542/safety-and-efficacy-of-apremilast-through-104-weeks-in-patients-with-moderate-to-severe-psoriasis-who-continued-on-apremilast-or-switched-from-etanercept-treatment-findings-from-the-liberate-study
#1
K Reich, M Gooderham, A Bewley, L Green, J Soung, R Petric, J Marcsisin, J Cirulli, R Chen, V Piguet
BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. OBJECTIVE: To evaluate long-term efficacy and safety of apremilast in biologic-naive patients with moderate to severe plaque psoriasis and safety of switching from etanercept to apremilast in the phase 3b LIBERATE trial. METHODS: Two hundred fifty patients were randomized to placebo, apremilast 30 mg BID, or etanercept 50 mg QW through Week 16; thereafter, all patients continued or switched to apremilast through Week 104 (extension phase)...
December 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29214695/psoriasis-improvement-after-gastric-bandage-in-a-patient-partial-responder-to-infliximab
#2
Giulia Odorici, Andrea Conti
Patients overweight or obese have more severe psoriasis than normal weight patients. Sometimes the excessive weight is related to a lack of efficacy of systemic treatment. We report a case of a psoriatic patient that experienced a dramatic improvement of psoriasis after weight loss surgery by gastric bandage. The great weight loss was accompanied by an effectiveness gain of response to infliximab. The mechanism responsible for this association is not certain, but it is probably multifactorial, involving genetic, environmental and immune-mediated factors...
December 7, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/29209945/psoriasis-in-skin-of-color-insights-into-the-epidemiology-clinical-presentation-genetics-quality-of-life-impact-and-treatment-of-psoriasis-in-non-white-racial-ethnic-groups
#3
REVIEW
Bridget P Kaufman, Andrew F Alexis
Psoriasis is a chronic inflammatory skin condition affecting diverse racial/ethnic groups throughout the world. Large population-based studies suggest that psoriasis occurs most often in individuals of European ancestry, followed by black and Hispanic individuals, although the true prevalence of psoriasis in non-white individuals is likely underestimated. Despite similarities in psoriasis between ethnic groups, there are notable differences in the presentation, quality-of-life impact, and treatment of psoriasis with important implications for the management of non-white individuals...
December 5, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29204894/the-development-of-the-genital-psoriasis-sexual-frequency-questionnaire-genps-sfq-to-assess-the-impact-of-genital-psoriasis-on-sexual-health
#4
Alice B Gottlieb, Brian Kirby, Caitriona Ryan, April N Naegeli, Russel Burge, Alison Potts Bleakman, Milena D Anatchkova, Jennifer Cather
INTRODUCTION: Patient-reported outcome measures (PROs) exist for psoriasis but not genital psoriasis (GenPs). METHODS: This cross-sectional, qualitative study in patients with moderate-to-severe GenPs was conducted to support development of a PRO for measuring the impact of GenPs on sexual activity and to establish content validity. The impacts of GenPs were identified in a literature review. Findings from the literature review were discussed with clinicians, and then patients with GenPs were interviewed...
December 4, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29204388/clinic-based-group-multi-professional-education-causes-significant-decline-in-psoriasis-severity-a-randomized-open-label-pilot-study
#5
Shubh Mohan Singh, Tarun Narang, Keshavamurthy Vinay, Aditi Sharma, Ashirbad Satapathy, Sanjeev Handa, Sunil Dogra
Background: The evidence for efficacy of psychoeducational interventions in psoriasis is not well researched. Objective: The objective of this study was to assess the benefits of a group, multi-professional, psychoeducational training in psoriasis. Materials and Methods: Adults with moderate-to-severe psoriasis were randomized into psychoeducational intervention plus treatment (intervention arm [IA]) and treatment as usual alone (control arm [CA]) groups using random number tables...
November 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/29197196/analysis-of-the-prevalence-of-mental-disorders-in-psoriasis-the-relevance-of-psychiatric-assessment-in-dermatology
#6
Bárbara Roque Ferreira, José Luís Pio-Abreu, José Pedro Reis, Américo Figueiredo
BACKGROUND: The boundary between Dermatology and Psychiatry has increasing recognition. Psoriasis is a common psychophysiological skin disease with a major impact on patient's quality of life and a paradigmatic example of a pathology in that boundary. Studies are needed to exactly point out the prevalence of specific psychopathology and mental disorders associated with psoriasis. This work intends to analyse the prevalence of psychopathology and psychiatric comorbidities in patients with psoriasis...
December 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/29193001/real-world-effect-of-biologics-on-quality-of-life-in-psoriasis
#7
A Y Finlay
No abstract text is available yet for this article.
November 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29171861/matching-adjusted-indirect-comparison-of-efficacy-in-patients-with-moderate-to-severe-plaque-psoriasis-treated-with-ixekizumab-versus-secukinumab
#8
R B Warren, A Brnabic, Daniel Saure, R G Langley, K See, J J Wu, A Schacht, L Mallbris, A Nast
BACKGROUND: Head-to-head randomised studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available. OBJECTIVE: Assess efficacy and quality of life with ixekizumab vs. secukinumab treatment using matching-adjusted indirect comparisons. METHODS: Psoriasis Area and Severity Index (PASI) improvement of at least 75%, 90% and 100% and Dermatology Life Quality Index (DLQI) 0/1 response rates for approved doses of ixekizumab (160 mg at Week 0, then 80 mg every two weeks for the first 12 weeks) and secukinumab (300 mg at Weeks 0, 1, 2, 3 and 4, then 300 mg every 4 weeks) treatment were compared using data from active (etanercept and ustekinumab) and placebo-controlled studies...
November 24, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29168976/biological-therapies-in-psoriasis-revisited
#9
Maria-Isabela Sârbu, Simona-Roxana Georgescu, Mircea Tampa, Alexandra-Elena Sârbu, Olga Simionescu
Psoriasis is a chronic, immune mediated disorder affecting approximately 2% of the population. Even in our days, patients with psoriasis are confronted with stigmatization and social rejection. As a result, their quality of life is significantly impaired. Biological therapies have revolutionized the treatment of moderate to severe psoriasis. The aim of this paper is to look over the most important biological therapies available for the management of plaque-type psoriasis.
November 27, 2017: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/29151062/instruments-to-assess-stigmatization-in-dermatology
#10
Dimitre Dimitrov, Jacek C Szepietowski
Stigmatization is the assignment of negative perceptions to an individual because of a perceived difference from the population at large. Skin conditions are frequently the reason of social rejection with a consequent negative influence on the personal and social life of patients. The aim of the current study was to review the available instruments that can be successfully utilized to measure the stigmatization level among dermatological patients. We performed our search on PubMed up to November 2016 and utilized combinations of key phrases containing such words as stigmatization, skin, dermatology, names of various skin conditions (psoriasis, vitiligo, acne, etc...
November 3, 2017: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/29136293/efficacy-and-safety-of-tofacitinib-for-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#11
REVIEW
C-M Kuo, T-H Tung, S-H Wang, C-C Chi
The effects of tofacitinib in treating moderate-to-severe plaque psoriasis were unclear. We aimed to assess the effects of tofacitinib in treating moderate-to-severe plaque psoriasis. We searched PubMed, Cochrane Central Register of Controlled Trials, and EMBASE for relevant randomised controlled trials (RCTs), and conducted a systematic review and meta-analysis. Four RCTs with 2,724 participants were included. Compared to placebo, tofacitinib significantly improved psoriasis (≥ 75% reduction in the Psoriasis Area and Severity Index score: 5 mg BID: risk difference (RD) 0...
November 14, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29131243/photodynamic-therapy-with-5-aminolevulinic-acid-suppresses-ifn-%C3%AE-induced-k17-expression-in-hacat-cells-via-mapk-pathway
#12
X-L Wang, Q Sun
OBJECTIVE: Psoriasis is a chronic inflammatory skin disorder that greatly affects the patient's quality of life. Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) has recently been applied for inflammatory dermatoses including psoriasis. However, the therapeutic effect of ALA-PDT is yet to be validated, and the underlying mechanisms remain unclear. MATERIALS AND METHODS: In this study, a psoriatic model was established by treating HaCaT cells with 250 U/ml IFN-γ for 48 h...
October 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29131033/adverse-reactions-to-biologics-in-psoriasis
#13
Stephen J Lockwood, Lisette M Prens, Alexa B Kimball
Psoriasis is a chronic autoimmune disease which affects millions of people worldwide. Not only can psoriasis itself be debilitating and significantly reduce an individual's quality of life, but it is also a risk factor for other systemic disorders, such as metabolic syndrome, cardiovascular disease, and malignancy. Tremendous strides were made in the treatment of psoriasis during the mid-to-late-20th century, including the emergence of topical corticosteroids and vitamin D analogs, methotrexate, systemic retinoids, and phototherapy...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29128966/is-the-dlqi-appropriate-for-medical-decision-making-in-psoriasis-patients
#14
Adrienn Katalin Poór, Valentin Brodszky, Márta Péntek, László Gulácsi, Gábor Ruzsa, Bernadett Hidvégi, Péter Holló, Sarolta Kárpáti, Miklós Sárdy, Fanni Rencz
Dermatology Life Quality Index (DLQI) is the most commonly applied measure of health-related quality of life (HRQoL) in psoriasis patients. It is among defining criteria of moderate-to-severe psoriasis and present in treatment guidelines. Our objective was to estimate preference-based HRQoL values (i.e., utilities) for hypothetical health states described by the 10 items of the DLQI in psoriasis patients. Moreover, we compare results to findings of a similar study previously conducted among the general public...
November 11, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/29114942/a-detailed-analysis-of-not-relevant-responses-on-the-dlqi-in-psoriasis-potential-biases-in-treatment-decisions
#15
F Rencz, A K Poór, M Péntek, P Holló, S Kárpáti, L Gulácsi, A Szegedi, É Remenyik, B Hidvégi, K Herszényi, H Jókai, Z Beretzky, V Brodszky
BACKGROUND: Dermatology Life Quality Index (DLQI) is the most common health-related quality of life measure in dermatology that is widely used in treatment guidelines for psoriasis. Eight out of the 10 questions of the DLQI offer a 'not relevant' response (NRR) option that is scored as the item had no impact on patients' life at all. OBJECTIVE: To explore the occurrence of NRRs on the DLQI in psoriasis patients, and to examine the effect of several socio-demographic and clinical factors on giving NRRs...
November 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29114862/fumaric-acid-esters-in-combination-with-a-6-week-course-of-narrow-band-uvb-provides-for-an-accelerated-response-as-compared-to-fumaric-acid-esters-monotherapy-in-patients-with-moderate-to-severe-plaque-psoriasis-a-randomized-prospective-clinical-study
#16
S Tzaneva, A Geroldinger, H Trattner, A Tanew
BACKGROUND: Fumaric acid esters are (FAE) safe and effective in patients with moderate to severe psoriasis but have a slow onset of action. A short-term combination with narrow-band UVB (NB UVB) may substantially accelerate the therapeutic response in the induction phase of treatment. OBJECTIVES: To assess the synergistic effect of a 6-week course of NB UVB phototherapy in addition to fumaric acid esters in adult patients with moderate to severe plaque psoriasis...
November 8, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29110556/the-impact-of-biologic-agents-on-health-related-quality-of-life-outcomes-in-patients-with-psoriasis
#17
Jillian Frieder, Dario Kivelevitch, Connie Tran Fiore, Saadeddine Saad, Alan Menter
Psoriasis is a common, immune-mediated skin disease often associated with significant physical and psychosocial impairment. Antipsoriatic biologic agents offer patients unparalleled treatment potential in regard to greater skin clearance and overall improved quality of life. Evaluation of the therapeutic efficacy of biologic agents on the full psoriasis disease burden must account for their impact on both physical symptoms, as well as patient-reported, health-related quality of life (HRQoL) measurements. Areas covered: Results from numerous clinical trials demonstrate the significant clinical efficacy of biological agents targeting tumor necrosis factor-α (TNF-α) and the interleukin (IL)-12/23 and IL-17 immune pathways...
November 7, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29110019/correlation-between-dermatology-life-quality-index-and-psoriasis-area-and-severity-index-in-patients-with-psoriasis-treated-with-ustekinumab
#18
Jeanette Halskou Hesselvig, Alexander Egeberg, Nikolai Dyrberg Loft, Claus Zachariae, Kristian Kofoed, Lone Skov
Biologic treatment for psoriasis is based on clinical evaluation and patient's quality of life. However, long-term correlation between Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) in real life has not been studied in patients treated with ustekinumab. All patients with psoriasis treated with ustekinumab at our department were included (n = 120) in this study. Correlation analyses between the change in PASI and DLQI and the individual subquestions in DLQI were performed using Spearman's rank correlation coefficient...
November 7, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/29108826/physical-activity-and-autoimmune-diseases-get-moving-and-manage-the-disease
#19
REVIEW
Kassem Sharif, Abdulla Watad, Nicola Luigi Bragazzi, Micheal Lichtbroun, Howard Amital, Yehuda Shoenfeld
Physical activity, by definition, is any skeletal muscle body movement that results in energy expenditure. In the last few decades, a plethora of scientific evidences have accumulated and confirmed the beneficial role of physical activity as a modifiable risk factor for a wide variety of chronic diseases including cardiovascular diseases (CVDs), diabetes mellitus and cancer, among others. Autoimmune diseases are a heterogeneous group of chronic diseases, which occur secondary to loss of self-antigen tolerance...
November 3, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29105621/adalimumab-etanercept-and-ustekinumab-for-treating-plaque-psoriasis-in-children-and-young-people-systematic-review-and-economic-evaluation
#20
Ana Duarte, Teumzghi Mebrahtu, Pedro Saramago Goncalves, Melissa Harden, Ruth Murphy, Stephen Palmer, Nerys Woolacott, Mark Rodgers, Claire Rothery
BACKGROUND: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments currently licensed for psoriasis in children. OBJECTIVE: To determine the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and ustekinumab within their respective licensed indications for the treatment of plaque psoriasis in children and young people...
November 2017: Health Technology Assessment: HTA
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"